Circulating C1q/TNF-related protein-12 levels are associated with the severity of coronary artery disease

Background: Coronary artery disease (CAD) is the world's largest cause of death. The association of CAD with inflammation is well established. Recently, it has been confirmed that the C1q/TNF-related protein 12 (CTRP12) has a great anti-inflammatory effect. However, few data are available regarding the serum CTRP12 concentration levels in CAD patients. Objective: The study was performed to evaluate the correlation between the serum levels of CTRP12 and the CAD severity regarding to the number of affected vessels. Methods: About 200 suspected CAD patients and 50 healthy ones as a control, were evaluated based on casecontrol study. According to the results of angiography, patients were divided into CAD+ (n = 150) with any major coronary artery stenosis >= 50% and CAD- (n = 50) with <50% stenosis of the arteries. The CAD+patients were categorized into one- (1VD), two- (2VD) and three-vessel disease (3VD) based on the number of stenotic vessels. In the current study, different parameters such as CTRP12, tumor necrosis factor alpha (TNF-alpha), interleukin-6 (IL-6), total oxidant status (TOS), total antioxidant capacity (TAC), and malondialdehyde (MDA) levels were evaluated, and also lipid profiles, hs-CRP and demographic factors were investigated as well. Results: Data revealed that CTRP12 and TAC levels in CAD + group were significantly lower than control subjects (P < 0.05). CTRP12 levels were found to be significantly lower in the 3VD compared with 1VD and 2VD subgroups (p < 0.01 and p < 0.05, respectively). Conclusion: Our results confirmed that serum CTRP12 level is inversely associated with CAD severity. Therefore, it may be used as a prediction marker for CAD.

Automated summary

CAD is a major cause of death globally, and its association with inflammation is known. Recent research shows that CTRP12 has strong anti-inflammatory effects, and this study aimed to assess its levels in relation to CAD severity.